Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland. Show more
Chemin de Blandonnet 8, Geneva, 1214, Switzerland
Market Cap
38.65B
52 Wk Range
$71.55 - $99.20
Previous Close
$77.32
Open
$77.38
Volume
1,508,898
Day Range
$77.30 - $78.75
Enterprise Value
41.6B
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
0.19%
Institutional Own.
67.83%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
TRYPTYR® (acoltremon ophthalmic solution 0.003%; AR-15512) Details Eye disease , Dry eye syndrome, Opthalmolgy, Metastatic merkel cell carcinoma | Approved Quarterly sales | |
Approved Quarterly sales | ||
Rocklatan (Roclanda - EU) (netarsudil (ROCK - rho kinase inhib) & latanoprost (ophthalmic solution) Details Intra-ocular pressure, Opthalmolgy, Eye disease | Approved Quarterly sales | |
AR-1105 Details Eye disease , Diabetic macular edema, Diabetes | Phase 3 Update |
